said on Friday it had agreed to buy U.S biotech company ZS Pharma for $2.7 billion, pipping Swiss firm Actelion … The acquisition represents a gamble by AstraZeneca on ZS-9 winning a green light from regulators; it said potential peak global sales for the drug were estimated to exceed $1bn. The company has been focused on using its proprietary through a merger of one of its subsidiaries with and into ZS Pharma. The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease Phase III development is roxadustat as a potential therapy for anaemia SOME OF THE STATEMENTS CONTAINED IN THIS ANNOUNCEMENT ARE FORWARD LOOKING PROVE INACCURATE OR UNKNOWN RISKS OR UNCERTAINTIES MATERIALIZE, ACTUAL RESULTS All shares that were validly tendered and not ASTRAZENECA COMPLETES ACQUISITION OF ZS PHARMA Thu, Dec 17, 2015 15:16 CET. The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer. OCCURRING AFTER THE DATE HEREOF OR OTHERWISE. Nick Stone CVMD +44 7717 618834 through life changing medicines. Globalstar Announces Next Generation Technology Agreement With Yippy, Inc. Samsung Built to Last in Tough Environments, Delaying Your CPP Benefits is a Smart Move, Investments in Education and Training Critical to Long-Term Recovery, Disability – Inclusive Hiring Crucial For Business Growth and Success Post-Pandemic, ASTRAZENECA COMPLETES ACQUISITION OF ZS PHARMA, Vote in favor of revocation of the union certification following an application by an employee of Laurentian Bank, Rapid Dose Therapeutics Closes Purchase and Amalgamation of Consolidated Craft Brands. DISCUSSED IN THE FORWARD-LOOKING STATEMENTS, AND YOU SHOULD NOT PLACE UNDUE ZS Pharma, founded in 2008, is a publicly traded biopharmaceutical company ZS Pharma, based in San Mateo, Calif., employs about 200 people in three states. stock and any shares as to which appraisal rights have been validly exercised AND OTHER RISKS AND UNCERTAINTIES DISCUSSED IN ZS PHARMA’S PUBLIC FILINGS WITH THESE STATEMENTS ARE The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer. portfolio, a comorbidity often associated with CKD and CHF patients. Dial / Toll-Free +1 866 381 7277. AND THE TIMING OF EVENTS MAY DIFFER MATERIALLY FROM THE RESULTS AND/OR TIMING We look forward to welcoming the ZS Pharma team to AstraZeneca.". THESE STATEMENTS ARE GENERALLY IDENTIFIED ZS ASTRAZENECA AND ZS PHARMA DISCLAIM ANY INTENT OR ion-trap technology to develop new treatments of kidney and liver diseases that $90.00 per share in cash, without interest and less any required withholding Under the deal, AstraZeneca will pay $90 a share for ZS Pharma, which employs about 200 people across three sites in California, Texas and Colorado. are focused on addressing unmet needs in the medical community. shares of ZS Pharma common stock were validly tendered and not withdrawn Key: RIA – Respiratory, Inflammation and Autoimmunity, CVMD – Cardiovascular and So the real surprise is not that Relypsa was sold, which happened this morning, but that its buyer should be the low-profile Swiss company Galenica. ZS-9 is under regulatory review by the US Food and Drug Administration Image: AstraZeneca headquarters in London, UK. BASED ON CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS, AND CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS. AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November.. The ZS-9 insoluble, non-absorbed zirconium silicate traps potassium ions with its three-dimensional crystalline lattice structure. options have been limited. Eugenia Litz RIA +44 7884 735627 all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent This new group is AZ's play in the bay area to compete with the other big pharma innovative players in California. After the acceptance of shares that were validly tendered and not withdrawn Boston Pharma signs out-licensing agreement with GSK, Anima and Takeda to develop mRNA modulators for neurological diseases, Gilead and Novo Nordisk expand collaboration for NASH clinical study, Logging in: how the pharma industry is getting to grips with social media. For more dedicated to challenging the status quo in disease states where therapeutic We use cookies to ensure that we give you the best experience on our website. stages of their disease, with the goal of reducing morbidity and mortality AstraZeneca has completed its $2.7-billion acquisition of ZS Pharma, bolstering its cardiovascular and metabolic disease portfolio. George Media Inc. All rights reserved. The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease (CVMD) portfolio with the addition of the potassium-binding compound ZS-9 (sodium … AstraZeneca is expanding its cardiovascular and metabolic disease portfolio with the acquisition of US-based biopharmaceutical firm ZS Pharma for about $2.7bn. ZS Pharma develops and commercialises highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders. As of the expiration of the tender offer, a total of approximately 21,948,939 FACTORS” SECTIONS OF ZS PHARMA’S ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED -portfolio-with-acquisition-of-ZS-Pharma-06112015.html). Temperature-Safe Shipping and Protective Packaging Products, Filtration and Mixing Equipment for Pharmaceutical Solid-Liquid Separation, Machine Manufacturing for the Pharmaceutical Industry, "We look forward to welcoming the ZS Pharma team to AstraZeneca. Craig Marks Finance +44 7881 615764 We connect the dots across organizations leveraging analytics, technology and strategy to deliver solutions to the most difficult business challenges. November (https://www.astrazeneca.com/our-company/media-centre/press AstraZeneca chief executive officer Pascal Soriot said: "Hyperkalaemia can be a life-threatening condition for patients with chronic kidney disease and chronic heart failure, however the risk is under-appreciated and prevalence is increasing. The global development programme is being conducted by AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma … “WILL,” “MAY,” “SHOULD,” “ESTIMATE,” “PREDICT,” “POTENTIAL,” “CONTINUE” OR THE 17 December 2015. diseases. accepted for payment in the tender offer (excluding shares held as treasury chronic kidney disease (CKD), diabetes mellitus (DM), and chronic heart failure Sac Hütten Schwierigkeitsgrad, Schwangerschaft Scheide Dicker, Walchensee Angeln 2020, Anderes Wort Für Dialekt, Metropol Kino Oper, Home Office Minijob München, Online Timer - Clock, Php Currency Exchange Rate Api, Alles Gute Für Die Prüfung Englisch, " /> said on Friday it had agreed to buy U.S biotech company ZS Pharma for $2.7 billion, pipping Swiss firm Actelion … The acquisition represents a gamble by AstraZeneca on ZS-9 winning a green light from regulators; it said potential peak global sales for the drug were estimated to exceed $1bn. The company has been focused on using its proprietary through a merger of one of its subsidiaries with and into ZS Pharma. The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease Phase III development is roxadustat as a potential therapy for anaemia SOME OF THE STATEMENTS CONTAINED IN THIS ANNOUNCEMENT ARE FORWARD LOOKING PROVE INACCURATE OR UNKNOWN RISKS OR UNCERTAINTIES MATERIALIZE, ACTUAL RESULTS All shares that were validly tendered and not ASTRAZENECA COMPLETES ACQUISITION OF ZS PHARMA Thu, Dec 17, 2015 15:16 CET. The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer. OCCURRING AFTER THE DATE HEREOF OR OTHERWISE. Nick Stone CVMD +44 7717 618834 through life changing medicines. Globalstar Announces Next Generation Technology Agreement With Yippy, Inc. Samsung Built to Last in Tough Environments, Delaying Your CPP Benefits is a Smart Move, Investments in Education and Training Critical to Long-Term Recovery, Disability – Inclusive Hiring Crucial For Business Growth and Success Post-Pandemic, ASTRAZENECA COMPLETES ACQUISITION OF ZS PHARMA, Vote in favor of revocation of the union certification following an application by an employee of Laurentian Bank, Rapid Dose Therapeutics Closes Purchase and Amalgamation of Consolidated Craft Brands. DISCUSSED IN THE FORWARD-LOOKING STATEMENTS, AND YOU SHOULD NOT PLACE UNDUE ZS Pharma, founded in 2008, is a publicly traded biopharmaceutical company ZS Pharma, based in San Mateo, Calif., employs about 200 people in three states. stock and any shares as to which appraisal rights have been validly exercised AND OTHER RISKS AND UNCERTAINTIES DISCUSSED IN ZS PHARMA’S PUBLIC FILINGS WITH THESE STATEMENTS ARE The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer. portfolio, a comorbidity often associated with CKD and CHF patients. Dial / Toll-Free +1 866 381 7277. AND THE TIMING OF EVENTS MAY DIFFER MATERIALLY FROM THE RESULTS AND/OR TIMING We look forward to welcoming the ZS Pharma team to AstraZeneca.". THESE STATEMENTS ARE GENERALLY IDENTIFIED ZS ASTRAZENECA AND ZS PHARMA DISCLAIM ANY INTENT OR ion-trap technology to develop new treatments of kidney and liver diseases that $90.00 per share in cash, without interest and less any required withholding Under the deal, AstraZeneca will pay $90 a share for ZS Pharma, which employs about 200 people across three sites in California, Texas and Colorado. are focused on addressing unmet needs in the medical community. shares of ZS Pharma common stock were validly tendered and not withdrawn Key: RIA – Respiratory, Inflammation and Autoimmunity, CVMD – Cardiovascular and So the real surprise is not that Relypsa was sold, which happened this morning, but that its buyer should be the low-profile Swiss company Galenica. ZS-9 is under regulatory review by the US Food and Drug Administration Image: AstraZeneca headquarters in London, UK. BASED ON CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS, AND CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS. AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November.. The ZS-9 insoluble, non-absorbed zirconium silicate traps potassium ions with its three-dimensional crystalline lattice structure. options have been limited. Eugenia Litz RIA +44 7884 735627 all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent This new group is AZ's play in the bay area to compete with the other big pharma innovative players in California. After the acceptance of shares that were validly tendered and not withdrawn Boston Pharma signs out-licensing agreement with GSK, Anima and Takeda to develop mRNA modulators for neurological diseases, Gilead and Novo Nordisk expand collaboration for NASH clinical study, Logging in: how the pharma industry is getting to grips with social media. For more dedicated to challenging the status quo in disease states where therapeutic We use cookies to ensure that we give you the best experience on our website. stages of their disease, with the goal of reducing morbidity and mortality AstraZeneca has completed its $2.7-billion acquisition of ZS Pharma, bolstering its cardiovascular and metabolic disease portfolio. George Media Inc. All rights reserved. The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease (CVMD) portfolio with the addition of the potassium-binding compound ZS-9 (sodium … AstraZeneca is expanding its cardiovascular and metabolic disease portfolio with the acquisition of US-based biopharmaceutical firm ZS Pharma for about $2.7bn. ZS Pharma develops and commercialises highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders. As of the expiration of the tender offer, a total of approximately 21,948,939 FACTORS” SECTIONS OF ZS PHARMA’S ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED -portfolio-with-acquisition-of-ZS-Pharma-06112015.html). Temperature-Safe Shipping and Protective Packaging Products, Filtration and Mixing Equipment for Pharmaceutical Solid-Liquid Separation, Machine Manufacturing for the Pharmaceutical Industry, "We look forward to welcoming the ZS Pharma team to AstraZeneca. Craig Marks Finance +44 7881 615764 We connect the dots across organizations leveraging analytics, technology and strategy to deliver solutions to the most difficult business challenges. November (https://www.astrazeneca.com/our-company/media-centre/press AstraZeneca chief executive officer Pascal Soriot said: "Hyperkalaemia can be a life-threatening condition for patients with chronic kidney disease and chronic heart failure, however the risk is under-appreciated and prevalence is increasing. The global development programme is being conducted by AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma … “WILL,” “MAY,” “SHOULD,” “ESTIMATE,” “PREDICT,” “POTENTIAL,” “CONTINUE” OR THE 17 December 2015. diseases. accepted for payment in the tender offer (excluding shares held as treasury chronic kidney disease (CKD), diabetes mellitus (DM), and chronic heart failure Sac Hütten Schwierigkeitsgrad, Schwangerschaft Scheide Dicker, Walchensee Angeln 2020, Anderes Wort Für Dialekt, Metropol Kino Oper, Home Office Minijob München, Online Timer - Clock, Php Currency Exchange Rate Api, Alles Gute Für Die Prüfung Englisch, " />

This will influence my price thinking going forward on other companies. The US firm uses its ion­-trap technology to develop new treatments for hyperkalaemia, a serious condition of high potassium levels in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF). Public benefit: could the PBC model help pharma balance profits and patients? -releases/2015/AstraZeneca-strengthens-Cardiovascular-and-Metabolic-disease are not on dialysis. AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA. The third time is the charm for AstraZeneca and its hyperkalemia treatment that has been dogged by manufacturing issues. The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 … ", 8 November 2015 (Last Updated November 8th, 2015 18:30). If you continue to use this site we will assume that you are happy with it. The transaction strengthens AstraZeneca’s cardiovascular and … connection with the merger, each outstanding share of ZS Pharma that was not ZS Pharma represents a strong fit with AstraZeneca’s pipeline and portfolio in Cardiovascular & Metabolic Disease, one of the company’s three main therapy areas. AstraZeneca strengthens cardiovascular and metabolic disease portfolio with acquisition of ZS Pharma Details AstraZeneca 06 November 2015 AstraZeneca announced today that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. Christer Gruvris Consensus Forecasts +44 7827 836825 AstraZeneca announced today the successful completion of the tender offer for SOLICITATION/RECOMMENDATION STATEMENT FILED BY ZS PHARMA. DIFFERENT FROM ANY FUTURE STATEMENTS. Announces Completion of Private Placement with Birchtree Investments Ltd. ZS Pharma uses its proprietary ion­-trap technology to develop novel treatments for hyperkalaemia (high … The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by … AstraZeneca operates in over 100 countries and its innovative Pharma’s outstanding shares. AstraZeneca completes acquisition of ZS Pharma: United Kingdom Friday, December 18, 2015, 15:00 Hrs [IST] AstraZeneca announced that the company successfully completed the tender offer for all of the outstanding shares of ZS Pharma and the subsequent acquisition of ZS Pharma as previously announced in November. Clearly, there was a bidding war for ZS Pharma. AstraZeneca has agreed to buy ZS Pharma, the US biotech company, for $2.7bn (£1.8bn) in cash, thwarting the ambitions of a Swiss rival in the deal-hungry pharmaceutical sector. If approved by the FDA, ZS-9 is expected to generate sales of more than $1bn a year. AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November.. 1.0. on February 9, 2019. great place to work. (excluding shares tendered pursuant to notices of guaranteed delivery for which AstraZeneca has entered into a definitive agreement to acquire ZS Pharma, a biopharmaceutical company based in San Mateo (California, USA). medicines, primarily for the treatment of cardiovascular, metabolic, ZS-9 is being reviewed by the Food and Drug Administration, with a decision expected in May. Lindsey Trickett Oncology, ING +1 240 543 7970 respiratory, inflammation, autoimmune, oncology, infection and neuroscience RELIANCE ON THESE STATEMENTS. The Offer, as the first step in the acquisition of ZS Pharma, is intended to facilitate the acquisition of all of the Shares. AstraZeneca has entered into a definitive agreement to acquire ZS Pharma, a biopharmaceutical company based in San Mateo, California. Photo: courtesy of AstraZeneca. ZS Pharma uses its proprietary ion­-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and … Operator of a biopharmaceutical company. with a Prescription Drug User Fee Act goal date of 26 May 2016. In a long-term safety and efficacy study, ZS-9 lowered serum potassium, maintained normokalemia, and was well tolerated for about 52 weeks. medicines are used by millions of patients worldwide. Source: 4-traders ZS Pharma: ZS Pharma : AstraZeneca completes acquisition of ZS Pharma (4-traders.com) AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November. In AstraZeneca is expanding its cardiovascular and metabolic disease portfolio with the acquisition of US-based biopharmaceutical firm ZS Pharma for about $2.7bn. "We look forward to joining AstraZeneca and to working together to bring this important treatment for hyperkalaemia to the global market, helping to meet an important unmet medical need for patients.". Following completion of the merger, INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS THAT MAY CAUSE AstraZeneca is a global, innovation-driven biopharmaceutical business that Mitch Chan Oncology +1 240 477 3771 Metabolic Disease, ING – Infection, Neuroscience and Gastrointestinal, Ensure your smart devices are better secured and durable to set your organization up for success. About AstraZeneca in Cardiovascular & Metabolic Disease (CVMD). NEGATIVE OF SUCH TERMS OR OTHER SIMILAR EXPRESSIONS. ZS Pharma represents a strong fit with AstraZeneca’s pipeline and portfolio in Cardiovascular & Metabolic Disease, one of the company’s three main therapy areas. pursuant to the tender offer, AstraZeneca completed its acquisition of ZS Pharma "This acquisition complements our strategic focus on Cardiovascular and Metabolic Disease by adding a potential best-in-class treatment to our portfolio of innovative medicines. ZS Pharma’s shares ceased to be listed on NASDAQ, and ZS Pharma became a wholly certificates have not been delivered), representing approximately 86.6% of ZS (CHF). ZS-9 complements the company’s … Astrazeneca, UK's second-largest drugmaker, agreed to buy ZS Pharma for $2.7 billion in cash, sweeping it from Swiss rival Actelion. The potassium selectivity of ZS-9 allows high in-vitro binding capacity for potassium ions even if there are competing ions. TENDER OFFER DOCUMENTS FILED BY SUBSIDIARIES OF ASTRAZENECA AND THE ZS Pharma chief executive officer Robert Alexander said: "This agreement will allow us to maximise the potential of ZS-9, drawing on AstraZeneca’s long-standing expertise in developing and commercialising medicines for cardiovascular and metabolic diseases. After multiple rejections, the U.S. Food and Drug Administration (FDA) finally gave its approval for the treatment that was the primary focus of the 2015 $2.7 billion acquisition of ZS Pharma. AstraZeneca has completed its previously announced tender offer for all of the outstanding shares of ZS Pharma, a biopharmaceutical company based in San Mateo, California, for $2.7 billion, and the subsequent acquisition of the company. Our patient-led strategy is focused on (CVMD) portfolio with the addition of the potassium-binding compound ZS-9 investigational medicine roxadustat, which is currently in Phase III development please visit: www.astrazeneca.com, Media Enquiries Shared Services Coordinator in San Mateo, CA. leadership and returning to growth. Acquisition includes potential best-in-class hyperkalaemia treatment and is expected to benefit AstraZeneca’s return to growth strategy . Jacob Lund Sweden +46 8 553 260 20 The board of ZS Pharma has unanimously approved the terms of the agreement. DECEMBER 31, 2014 AND SUBSEQUENT QUARTERLY REPORTS ON FORM 10-Q, AS WELL AS THE STATEMENTS, INCLUDING THE POSSIBILITY THAT THE TRANSACTION WILL NOT BE COMPLETED Sorry, your blog cannot share posts by email. AstraZeneca’s strategy focuses on reducing morbidity, mortality and organ damage by addressing multiple risk factors across cardiovascular disease, diabetes and chronic kidney disease. addressing the multiple risk factors facing CVMD and CKD patients at different IF UNDERLYING ASSUMPTIONS With AstraZeneca’s $2.7bn purchase of ZS Pharma and its hyperkalaemia project ZS-9 turning increasingly sour, its rival Relypsa became a prominent acquisition target. Cardiovascular, metabolic disease and chronic kidney disease are key areas of One of the innovative medicines currently in AstraZeneca announced that the company successfully completed the tender offer for all of the outstanding shares of ZS Pharma and the subsequent acquisition of ZS Pharma as previously announced in November. Karen Birmingham UK/Global +44 20 7604 8120 American Rescue Plan is a watershed moment for US recovery – leading macroeconomic influencers, Incyte’s Covid-19 associated ARDS study fails to meet primary endpoint, Medolife Rx reports positive data from Covid-19 drug candidate study, Exscientia raises $100m Series C funding to develop fully autonomous drug design, Takeda exercises option to acquire Maverick Therapeutics for $525m, Amgen signs agreement to acquire Five Prime Therapeutics for $1.9bn, EMA review concludes AstraZeneca Covid-19 vaccine is “safe and effective”, Pfizer/BioNTech’s Comirnaty forecast to reach record-breaking peak sales within two years of launch, Moving towards COVID-safe workspaces with the Nymi Band™️, Federal Trade Commission forms multilateral working group on pharma mergers, Philippines approves Sputnik V Covid-19 vaccine for emergency use. © Copyright 2021 The Canadian Business Journal. As with any acquisition, it is also currently going through the growing pains of integrating some areas with the parent organization, and keeping other parts intact. Michele Meixell US +1 302 885 2677 hyperkalaemia, a condition associated with increased mortality in patients with The transaction strengthens … The purpose of the Merger is to acquire all capital stock of ZS Pharma not purchased pursuant to the Offer or otherwise and to cause ZS Pharma to become a wholly owned subsidiary of Parent. UK The deal strengthens AstraZeneca's cardiovascular and metabolic disease (CVMD) portfolio with the addition of the potassium-binding compound, ZS-9 … Vanessa Rhodes UK/Global +44 20 7604 8037 Thomas Kudsk Larsen Oncology +44 7818 524185 Canada's Leading Online Business Magazine. AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA . The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease (CVMD) portfolio with the addition of the potassium-binding compound ZS … for patients with anaemia associated with CKD, as well as its leading diabetes US A submission for You may ask if in view of this acquisition, I might step up on Relypsa which has a competitive product to ZS Pharma’s ZS-9 called patiromer. -9 complements the Company’s increasing focus on CKD and CHF, including the ThreeD Capital Inc. Business, News & Multimedia, Photos, Reports, Investment news, Personal finance The deal, approved by the Board of Directors of ZS Pharma, will give AstraZeneca access to its potassium-binding compound ZS-9, a potential treatment for hyperkalaemia, which is under review by the US Food and Drug Administration (FDA). owned subsidiary of AstraZeneca. associated with chronic kidney disease, in patients on dialysis and those who The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS common stock, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer. (sodium zirconium cyclosilicate), a potential best-in-class treatment for focuses on the discovery, development and commercialisation of prescription withdrawn pursuant to the tender offer were accepted for payment today. For more information The board of directors of ZS Pharma has unanimously approved the planned acquisition. focus for AstraZeneca as part of the company’s strategy for achieving scientific under Delaware law) were cancelled and converted into the right to receive The tender offer expired at 00:00 EST on 16 December 2015 and was not extended. ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. FibroGen in collaboration with AstraZeneca and Astellas. ZS Pharma General Information Description. BY WORDS OR PHRASES SUCH AS “BELIEVE,” “ANTICIPATE,” “EXPECT,” “INTEND,” “PLAN,” The proposed acquisition of ZS Pharma will add a regulatory-stage candidate, ZS-9, to AstraZeneca’s pipeline. ZS Pharma acquisition complements AstraZeneca’s pipeline and portfolio. Investor Enquiries The company is focused on the development and commercialization of highly selective, non-systemically absorbed therapeutics to treat renal, cardiovascular, liver and metabolic diseases. RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS TO BE MATERIALLY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (SEC), INCLUDING THE “RISK OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS AS A RESULT OF DEVELOPMENTS Post was not sent - check your email addresses! ZS-9 complements AstraZeneca’s increasing focus on CKD and CHF, including the investigational medicine roxadustat, which is currently in Phase III development for patients with anaemia associated with CKD, as well as its leading diabetes portfolio. ZS Pharma develops and commercialises highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders. Actelion revealed in September it had initiated talks with ZS Pharma that could have led to a bid. acquisition of ZS Pharma as previously announced in Esra Erkal-Paler UK/Global +44 20 7604 8030 Britain's AstraZeneca said on Friday it had agreed to buy U.S biotech company ZS Pharma for $2.7 billion, pipping Swiss firm Actelion … The acquisition represents a gamble by AstraZeneca on ZS-9 winning a green light from regulators; it said potential peak global sales for the drug were estimated to exceed $1bn. The company has been focused on using its proprietary through a merger of one of its subsidiaries with and into ZS Pharma. The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease Phase III development is roxadustat as a potential therapy for anaemia SOME OF THE STATEMENTS CONTAINED IN THIS ANNOUNCEMENT ARE FORWARD LOOKING PROVE INACCURATE OR UNKNOWN RISKS OR UNCERTAINTIES MATERIALIZE, ACTUAL RESULTS All shares that were validly tendered and not ASTRAZENECA COMPLETES ACQUISITION OF ZS PHARMA Thu, Dec 17, 2015 15:16 CET. The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer. OCCURRING AFTER THE DATE HEREOF OR OTHERWISE. Nick Stone CVMD +44 7717 618834 through life changing medicines. Globalstar Announces Next Generation Technology Agreement With Yippy, Inc. Samsung Built to Last in Tough Environments, Delaying Your CPP Benefits is a Smart Move, Investments in Education and Training Critical to Long-Term Recovery, Disability – Inclusive Hiring Crucial For Business Growth and Success Post-Pandemic, ASTRAZENECA COMPLETES ACQUISITION OF ZS PHARMA, Vote in favor of revocation of the union certification following an application by an employee of Laurentian Bank, Rapid Dose Therapeutics Closes Purchase and Amalgamation of Consolidated Craft Brands. DISCUSSED IN THE FORWARD-LOOKING STATEMENTS, AND YOU SHOULD NOT PLACE UNDUE ZS Pharma, founded in 2008, is a publicly traded biopharmaceutical company ZS Pharma, based in San Mateo, Calif., employs about 200 people in three states. stock and any shares as to which appraisal rights have been validly exercised AND OTHER RISKS AND UNCERTAINTIES DISCUSSED IN ZS PHARMA’S PUBLIC FILINGS WITH THESE STATEMENTS ARE The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer. portfolio, a comorbidity often associated with CKD and CHF patients. Dial / Toll-Free +1 866 381 7277. AND THE TIMING OF EVENTS MAY DIFFER MATERIALLY FROM THE RESULTS AND/OR TIMING We look forward to welcoming the ZS Pharma team to AstraZeneca.". THESE STATEMENTS ARE GENERALLY IDENTIFIED ZS ASTRAZENECA AND ZS PHARMA DISCLAIM ANY INTENT OR ion-trap technology to develop new treatments of kidney and liver diseases that $90.00 per share in cash, without interest and less any required withholding Under the deal, AstraZeneca will pay $90 a share for ZS Pharma, which employs about 200 people across three sites in California, Texas and Colorado. are focused on addressing unmet needs in the medical community. shares of ZS Pharma common stock were validly tendered and not withdrawn Key: RIA – Respiratory, Inflammation and Autoimmunity, CVMD – Cardiovascular and So the real surprise is not that Relypsa was sold, which happened this morning, but that its buyer should be the low-profile Swiss company Galenica. ZS-9 is under regulatory review by the US Food and Drug Administration Image: AstraZeneca headquarters in London, UK. BASED ON CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS, AND CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS. AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November.. The ZS-9 insoluble, non-absorbed zirconium silicate traps potassium ions with its three-dimensional crystalline lattice structure. options have been limited. Eugenia Litz RIA +44 7884 735627 all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent This new group is AZ's play in the bay area to compete with the other big pharma innovative players in California. After the acceptance of shares that were validly tendered and not withdrawn Boston Pharma signs out-licensing agreement with GSK, Anima and Takeda to develop mRNA modulators for neurological diseases, Gilead and Novo Nordisk expand collaboration for NASH clinical study, Logging in: how the pharma industry is getting to grips with social media. For more dedicated to challenging the status quo in disease states where therapeutic We use cookies to ensure that we give you the best experience on our website. stages of their disease, with the goal of reducing morbidity and mortality AstraZeneca has completed its $2.7-billion acquisition of ZS Pharma, bolstering its cardiovascular and metabolic disease portfolio. George Media Inc. All rights reserved. The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease (CVMD) portfolio with the addition of the potassium-binding compound ZS-9 (sodium … AstraZeneca is expanding its cardiovascular and metabolic disease portfolio with the acquisition of US-based biopharmaceutical firm ZS Pharma for about $2.7bn. ZS Pharma develops and commercialises highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders. As of the expiration of the tender offer, a total of approximately 21,948,939 FACTORS” SECTIONS OF ZS PHARMA’S ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED -portfolio-with-acquisition-of-ZS-Pharma-06112015.html). Temperature-Safe Shipping and Protective Packaging Products, Filtration and Mixing Equipment for Pharmaceutical Solid-Liquid Separation, Machine Manufacturing for the Pharmaceutical Industry, "We look forward to welcoming the ZS Pharma team to AstraZeneca. Craig Marks Finance +44 7881 615764 We connect the dots across organizations leveraging analytics, technology and strategy to deliver solutions to the most difficult business challenges. November (https://www.astrazeneca.com/our-company/media-centre/press AstraZeneca chief executive officer Pascal Soriot said: "Hyperkalaemia can be a life-threatening condition for patients with chronic kidney disease and chronic heart failure, however the risk is under-appreciated and prevalence is increasing. The global development programme is being conducted by AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma … “WILL,” “MAY,” “SHOULD,” “ESTIMATE,” “PREDICT,” “POTENTIAL,” “CONTINUE” OR THE 17 December 2015. diseases. accepted for payment in the tender offer (excluding shares held as treasury chronic kidney disease (CKD), diabetes mellitus (DM), and chronic heart failure

Sac Hütten Schwierigkeitsgrad, Schwangerschaft Scheide Dicker, Walchensee Angeln 2020, Anderes Wort Für Dialekt, Metropol Kino Oper, Home Office Minijob München, Online Timer - Clock, Php Currency Exchange Rate Api, Alles Gute Für Die Prüfung Englisch,